))
Highlights from ASH 2024 (Meeting Mic Re-Release)
Manage episode 456358480 series 3560286
Innhold levert av Healio, Shikha Jain, and MD. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Healio, Shikha Jain, and MD eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
In this special crossover episode of Oncology Overdrive, we bring you Healio coverage from the ASH Annual Meeting and Exhibition, as well as Healio’s top headlines from the meeting.
Gwen L. Nichols, MD, reviews a panel discussion on how hematologists and oncologists can best address patients’ concerns as AI’s role in medicine invariably expands. :24
Thomas G. Knight, MD, addresses financial toxicity for people with blood cancer. 6:29
Charles S. Abrams, MD, discusses results of the HIBISCUS trial and its implications for vaso-occlusive events. 16:30
Read the full coverage here:
AI in hematology: ‘The good, the bad and the ugly’
Mitigating financial toxicity ’better than any drug’ for people with cancer
Etavopivat could offer ‘great benefit’ in sickle cell disease
ASH recognizes Judith Kleinerman, MD, with Exemplary Service Award
GLP-1s reduce thrombosis risk among people with diabetes, regardless of obesity
We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Disclosures: Jain reports no financial disclosures. Abrams reports he is chair of the ASH Research Collaborative's Sickle Cell Disease Clinical Trials Network Oversight Committee. Knight reports no relevant financial disclosures. Nichols reports no relevant financial disclosures.
100 episoder
Del
